US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Notice of annual general meeting of Enorama Pharma AB (publ)

The shareholders of Enorama Pharma AB (publ), reg. no. 556716–5591 (the “Company” or “Enorama Pharma”), are hereby invited to attend the annual general meeting on 16 June 2026 at 14:30 at Advokatfirman Delphi’s premises at Nordenskiöldsgatan 11 A, 211 19 in Malmö. Right to participate and notification Anyone wishing to attend the meeting must: a. be registered as a shareholder in the share register prepared by Euroclear Sweden AB as of the record date of 8 June 2026, and b. notify the Company of their participation no later than 10 June 2026. Notification of participation

Enorama Pharma: PRESS RELEASE FROM THE EXTRAORDINARY GENERAL MEETING, AND FIRST CONTROL MEETING, IN ENORAMA PHARMA AB (PUBL)

On 7 April 2026, an extraordinary general meeting and first control meeting was held in Enorama Pharma AB (publ), reg. no. 556716-5591 (“Enorama Pharma” or the “Company”). Below is a summary of the resolution that was passed. Resolution on continuing the Company’s operations The general meeting resolved, in accordance with the board of directors’ primary proposal, that the Company shall continue its operations and not go into liquidation. The board of directors considers that the discussions regarding the injection of capital and various capital raising measures from existing and

Notice of extraordinary general meeting and first control meeting in Enorama Pharma AB (publ)

The shareholders of Enorama Pharma AB (publ), reg. no. 556716–5591 (the “Company” or “Enorama Pharma”), are hereby invited to attend an extraordinary general meeting on 7 April 2026 at 14.00 CEST at Advokatfirman Delphi’s premises at Nordenskiöldsgatan 11 A, 211 19 in Malmö. Right to participate and notification Anyone wishing to attend the general meeting shall: i. be registered as a shareholder in the share register prepared by Euroclear Sweden AB as of the record date of 26 March 2026, andii. notify the Company of their participation no later than 30 March 2026.

Enorama Pharma AB (publ) resolves to postpone the planned extraordinary general meeting

The board of directors of Enorama Pharma AB (publ), reg. no. 556716-5591, has resolved to postpone the extraordinary general meeting which was scheduled for Wednesday 11 March 2026 to Friday 20 March 2026. Due to the above, the board of directors has resolved to withdraw the notice of the extraordinary general meeting scheduled for Wednesday 11 March 2026 in its entirety, and no general meeting will therefore be held on this date. Notice of extraordinary general meeting on Friday 20 March 2026 at Advokatfirman Delphi’s premises at Nordenskiöldsgatan 11 A, 211 19 in Malmö will be sent

Notice of extraordinary general meeting in Enorama Pharma AB (publ)

The shareholders of Enorama Pharma AB (publ), reg. no. 556716–5591 (the “Company” or “Enorama Pharma”), are hereby invited to attend an extraordinary general meeting on 11 March 2026 at 14.00 CET at Advokatfirman Delphi’s premises at Nordenskiöldsgatan 11 A, 211 19 in Malmö. Right to participate and notification Anyone wishing to attend the general meeting shall: i. be registered as a shareholder in the share register prepared by Euroclear Sweden AB as of the record date of 3 March 2026, andii. notify the Company of their participation no later than 5 March 2026. Notification

Enorama Pharma AB (publ) postpones publication of its 2025 year-end report

Enorama Pharma AB (publ) (“Enorama Pharma” or the “Company”) today announces that the board of directors has decided to postpone the publication of the Company’s 2025 year-end report until 11 March 2026. The previously announced date for publication of the year-end report was 17 February 2026. The postponement of the publication of the year-end report is due to the Refuse-to-File decision from the U.S. Food and Drug Administration, as previously announced by Enorama Pharma on 2 February 2026, and the need to prepare a balance sheet for liquidation purposes. CONTACTEnorama Pharma AB (

Enorama Pharma AB (publ) decides to prepare a balance sheet for liquidation purposes

Enorama Pharma AB (publ) (“Enorama Pharma” or the “Company”) announces today that the board of directors has decided to prepare a balance sheet for liquidation purposes. The decision has been made due to the fact that the Company’s subsidiary Enorama Pharma Inc. (the “Subsidiary”) has received a decision on Refuse-to-File from the U.S. Food and Drug Administration, as previously announced by Enorama Pharma on 2 February 2026. The decision entails that the assets related to the Subsidiary may need to be revalued. The board of directors therefore considers that there is reason to believe that

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN ENORAMA PHARMA AB (PUBL)

On 2 December 2025 an extraordinary general meeting was held in Enorama Pharma AB (publ), reg. no. 556716-5591 (“Enorama Pharma” or the “Company”). Below is a summary of the adopted resolution. Resolution to approve related party transaction regarding loan agreement. The general meeting resolved to approve the loan agreement entered into between Enorama Pharma and the major shareholder DS Global Pte Limited (“DS Global”) on 7 November 2025 which was conditioned on the subsequent approval by the general meeting (the “Loan Agreement”). Through the Loan Agreement, DS Global provides a

Notice of extraordinary general meeting in Enorama Pharma AB (publ)

The shareholders of Enorama Pharma AB (publ), reg. no. 556716–5591 (the “Company” or “Enorama Pharma”), are hereby invited to attend an extraordinary general meeting on 2 December 2025 at 14.00 CET at Advokatfirman Delphi’s premises at Nordenskiöldsgatan 11 A, 211 19 in Malmö. Right to participate and notification Anyone wishing to attend the general meeting shall: i. be registered as a shareholder in the share register prepared by Euroclear Sweden AB as of the record date of 24 November 2025, andii. notify the Company of their participation no later than 26 November 2025.

Enorama Pharma AB (publ) Explores Divestment of Nicotine Replacement Therapy Chewing Gum Business

The board of directors at Enorama Pharma AB (“Enorama Pharma” or the “Company”) has decided to explore the possibility of divesting the part of the business developing and selling its nicotine replacement therapy (“NRT”) chewing gum, to focus on the continued expansion of its NIC-S nicotine pouch product line.   Enorama Pharma has developed a patented range of NRT chewing gums in two strengths and two flavors, featuring superior gum characteristics. The product is already registered in seven European countries. Former CEO Annette Agerskov will lead the divestment process.   “I

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe